Teachers Retirement System of The State of Kentucky Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Teachers Retirement System of The State of Kentucky raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,528 shares of the medical equipment provider’s stock after buying an additional 1,894 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.05% of Lantheus worth $2,203,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Aurora Investment Counsel raised its stake in Lantheus by 2.6% in the fourth quarter. Aurora Investment Counsel now owns 24,492 shares of the medical equipment provider’s stock valued at $1,656,000 after buying an additional 632 shares during the last quarter. Prelude Capital Management LLC raised its stake in Lantheus by 29.4% in the fourth quarter. Prelude Capital Management LLC now owns 61,518 shares of the medical equipment provider’s stock valued at $3,814,000 after buying an additional 13,980 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in Lantheus by 60.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 80,000 shares of the medical equipment provider’s stock valued at $4,960,000 after buying an additional 30,111 shares during the last quarter. Braidwell LP raised its stake in Lantheus by 71.7% in the fourth quarter. Braidwell LP now owns 495,100 shares of the medical equipment provider’s stock valued at $30,696,000 after buying an additional 206,800 shares during the last quarter. Finally, Superstring Capital Management LP purchased a new stake in Lantheus in the fourth quarter valued at about $3,404,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LNTH shares. Truist Financial increased their price target on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. JMP Securities restated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. B. Riley raised their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $99.17.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the completion of the sale, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,269 shares of company stock valued at $2,557,300. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Up 0.4 %

Lantheus stock opened at $81.48 on Friday. The firm has a market cap of $5.65 billion, a price-to-earnings ratio of 12.44 and a beta of 0.56. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $94.01. The business’s 50-day moving average price is $75.21 and its 200 day moving average price is $65.76. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping the consensus estimate of $1.40 by $0.11. The firm had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.